← brief for 2026-09-18 · Slowing decline

Efficacy and safety of telitacicept combined with standard of care in patients with proliferative lupus nephritis: a real-world retrospective study.

Key takeaways

This study looked at 112 people with lupus kidney disease. It compared a drug called telitacicept with standard care. It is a retrospective study, so it shows a link, not proof of cause. The drug may help control the disease.

Who did this work

Tian T (Rheumatology and Immunology Department, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.) · Zhang A (Rheumatology and Immunology Department, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.) · Liu X (Rheumatology and Immunology Department, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.) · Wu P (Rheumatology and Immunology Department, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.) · Li N (Rheumatology and Immunology Department, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.) · Zeng L (School of Foundation, Xi'an Jiaotong-Liverpool University, Suzhou, Jiangsu, China.) · Liu J (Rheumatology and Immunology Department, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.) · Qin L (Rheumatology and Immunology Department, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.) · Zeng J (Rheumatology and Immunology Department, The Affiliated Hospital of Guizhou Medical University, Guiyang, China [email protected].)

Source

Article · Europe PMC, CKD · 2026-09-12
https://doi.org/10.1136/lupus-2026-002191